To evaluate the effect of mitomycin C (MMC) on the exacerbation of corneal opacity that occurs in patients with granular corneal dystrophy type II (GCD II) after refractive corneal surface ablation.
Ten eyes of patients with GCD II who underwent refractive corneal surface ablation with MMC were compared with 10 eyes that were not treated with MMC. Best spectacle-corrected visual acuity, the degree of corneal opacity, and contrast sensitivity were evaluated at least 3 years after surgery. Corneal opacities were quantified using Pentacam densitometry maps.
No measured between-group value showed a statistically significant difference.
Simultaneous application of MMC does not prevent exacerbation of GCD II after refractive corneal surface ablation.
From the *Siloam Eye Hospital, Seoul, Korea; †Corneal Dystrophy Research Institute and ‡Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea; §Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA; ¶Yonsei Eye Center, Seoul, Korea; and ‖Department of Biology, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea.
Received for publication March 24, 2009; revision received July 27, 2009; accepted September 23, 2009.
Supported by a grant of the Korea Healthcare technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A080320).
Reprints: Eung Kweon Kim, MD, PhD, Department of Ophthalmology, Yonsei University College of Medicine, Seodaemungu Sinchondong 134, Seoul 120-752, Korea (e-mail: email@example.com).